Key Points
- Insider sale: VP Padmanabh Bhatt sold 710 shares at an average price of $44.44 for $31,552.40, reducing his stake by 4.67% to 14,508 shares; the transaction was disclosed in an SEC filing.
- Quarterly results missed expectations: Supernus reported $0.46 EPS vs. a $0.82 consensus and $170.0M revenue vs. $175.8M expected, with revenue up 9.3% year‑over‑year but a negative net margin of -2.81%.
- Mixed analyst outlook: Four analysts rate the stock a Buy, two Hold and one Sell, producing a MarketBeat consensus rating of "Hold" and a consensus price target of $61.60 amid several recent target increases and at least one downgrade.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) VP Padmanabh Bhatt sold 710 shares of the business's stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $44.44, for a total transaction of $31,552.40. Following the sale, the vice president owned 14,508 shares in the company, valued at $644,735.52. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Supernus Pharmaceuticals Stock Performance
NASDAQ SUPN opened at $51.48 on Friday. The firm has a market cap of $2.95 billion, a price-to-earnings ratio of -151.41, a PEG ratio of 0.60 and a beta of 0.71. The firm has a 50 day simple moving average of $48.27 and a 200-day simple moving average of $42.37. Supernus Pharmaceuticals, Inc. has a one year low of $29.16 and a one year high of $57.65.
Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last announced its earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.82 by ($0.36). Supernus Pharmaceuticals had a positive return on equity of 11.51% and a negative net margin of 2.81%.The business had revenue of $170.00 million for the quarter, compared to analysts' expectations of $175.82 million. During the same period in the previous year, the company earned $0.69 earnings per share. Supernus Pharmaceuticals's quarterly revenue was up 9.3% on a year-over-year basis. Equities analysts predict that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several research firms recently commented on SUPN. Cantor Fitzgerald boosted their target price on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 30th. Piper Sandler raised Supernus Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $40.00 to $65.00 in a research report on Thursday, October 9th. Zacks Research lowered shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Monday, December 8th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a report on Monday. Finally, Stifel Nicolaus boosted their price target on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a "hold" rating in a report on Friday. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $61.60.
View Our Latest Research Report on SUPN
Institutional Investors Weigh In On Supernus Pharmaceuticals
Hedge funds and other institutional investors have recently made changes to their positions in the business. Hantz Financial Services Inc. lifted its stake in Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company's stock worth $30,000 after purchasing an additional 281 shares during the last quarter. USA Financial Formulas acquired a new stake in Supernus Pharmaceuticals during the third quarter worth approximately $50,000. Smartleaf Asset Management LLC raised its holdings in Supernus Pharmaceuticals by 30.8% during the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company's stock worth $54,000 after purchasing an additional 268 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Supernus Pharmaceuticals during the 1st quarter worth approximately $46,000. Finally, Vestcor Inc acquired a new position in shares of Supernus Pharmaceuticals in the 3rd quarter valued at $67,000.
About Supernus Pharmaceuticals
(
Get Free Report)
Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.
The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
